Drug Profile
Research programme: protein-arginine deiminase inhibitors - Bristol-Myers Squibb
Alternative Names: PAD inhibitors - Bristol-Myers SquibbLatest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Padlock Therapeutics
- Developer Bristol-Myers Squibb; Evotec SE
- Class
- Mechanism of Action Protein-arginine deiminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 May 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 01 Apr 2016 Padlock Therapeutics has been acquired by and merged into Bristol-Myers Squibb
- 28 May 2015 Padlock Therapeutics in-licenses intellectual property, compounds, assays, data and crystal structures from GlaxoSmithKline